trifluoperazine has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atorvastatin was further predicted to bind to SARS-CoV-2's main protease and RNA-dependent RNA polymerase, and was shown to inhibit viral entry in our lung organoid model." | 1.62 | Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry. ( Bram, Y; Chen, S; Copertino, DC; Duarte, RRR; Han, Y; Iñiguez, LP; Marston, JL; Nixon, DF; Powell, TR; Schwartz, RE, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duarte, RRR | 1 |
| Copertino, DC | 1 |
| Iñiguez, LP | 1 |
| Marston, JL | 1 |
| Bram, Y | 1 |
| Han, Y | 1 |
| Schwartz, RE | 1 |
| Chen, S | 1 |
| Nixon, DF | 1 |
| Powell, TR | 1 |
1 other study available for trifluoperazine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Topics: Antiviral Agents; Atorvastatin; Cell Line; Coronavirus 3C Proteases; Coronavirus RNA-Dependent RNA P | 2021 |